Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis

Nancy Ho-Mahler,1 Beni Turner,2 Michael Eaddy,2 Mark L Hanke,1 Winnie W Nelson1 1Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA; 2Xcenda, Palm Harbor, FL, USACorrespondence: Nancy Ho-MahlerMallinckrodt Pharmaceuticals, 1425 U.S. Route 206, Bedminster, NJ 07921, USATel +1 747 239 0007Fax +1 314 65...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ho-Mahler N, Turner B, Eaddy M, Hanke ML, Nelson WW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	adrenocorticotropic hormone analogue acth immunomodulatory real-world patients Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/986e4a77b8e6411cb2e8470a0d405a3f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:986e4a77b8e6411cb2e8470a0d405a3f
record_format	dspace
spelling	oai:doaj.org-article:986e4a77b8e6411cb2e8470a0d405a3f2021-12-02T09:57:33ZTreatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis1179-156Xhttps://doaj.org/article/986e4a77b8e6411cb2e8470a0d405a3f2020-02-01T00:00:00Zhttps://www.dovepress.com/treatment-with-repository-corticotropin-injection-in-patients-with-rhe-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XNancy Ho-Mahler,1 Beni Turner,2 Michael Eaddy,2 Mark L Hanke,1 Winnie W Nelson1 1Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA; 2Xcenda, Palm Harbor, FL, USACorrespondence: Nancy Ho-MahlerMallinckrodt Pharmaceuticals, 1425 U.S. Route 206, Bedminster, NJ 07921, USATel +1 747 239 0007Fax +1 314 654 9440Email Nancy.Mahler@mnk.comPurpose: Repository corticotropin injection (RCI) is indicated for a number of autoimmune-mediated diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis (DM)/polymyositis (PM). To better understand the practice patterns and outcomes of RCI in patients with RA, SLE, or DM/PM, we conducted a retrospective medical record analysis.Patients and Methods: Participating providers selected deidentified medical records of patients meeting the inclusion criteria (age ≥ 18 years; physician-reported diagnosis of RA, SLE, or DM/PM; initiation of treatment with RCI between 1/1/2011 and 2/15/2016; ≥ 3 in-office visits with same site/provider). Collected data spanned 12 months before and after the first prescription date for RCI. Analyses included patient demographics and clinical history, RCI treatment patterns, and physician’s impression of change.Results: Data from 54 patients with RA, 30 patients with SLE, and 8 patients with DM/PM were analyzed. The most frequently reported reasons for initiating RCI were lack of efficacy with prior treatment, acute exacerbation of disease, and use as add-on to ongoing therapy. The most common initial RCI dosing, 80 U twice weekly, was used for 84% of patients with RA, 75% with SLE, and 86% with DM/PM. The mean duration of treatment was 4.8, 6.5, and 6.8 months for RA, SLE, and DM/PM, respectively. Among the 57 patients with data on physician’s impression of change with RCI, 78.1% of patients with RA, 94.7% with SLE, and 66.7% with DM/PM had a rating of “improved,” and the mean time to best impression of change was 3.4, 4.3, and 3.4 months for RA, SLE, and DM/PM, respectively.Conclusion: This study reports the real-world patient profile, use patterns, and outcomes of patients who used RCI for the treatment of RA, SLE, and DM/PM. These data can inform appropriate use and clinical expectations when using RCI.Keywords: adrenocorticotropic hormone, analogue, ACTH, immunomodulatory, real-world patientsHo-Mahler NTurner BEaddy MHanke MLNelson WWDove Medical Pressarticleadrenocorticotropic hormoneanalogueacthimmunomodulatoryreal-world patientsDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 12, Pp 21-28 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	adrenocorticotropic hormone analogue acth immunomodulatory real-world patients Diseases of the musculoskeletal system RC925-935
spellingShingle	adrenocorticotropic hormone analogue acth immunomodulatory real-world patients Diseases of the musculoskeletal system RC925-935 Ho-Mahler N Turner B Eaddy M Hanke ML Nelson WW Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
description	Nancy Ho-Mahler,1 Beni Turner,2 Michael Eaddy,2 Mark L Hanke,1 Winnie W Nelson1 1Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA; 2Xcenda, Palm Harbor, FL, USACorrespondence: Nancy Ho-MahlerMallinckrodt Pharmaceuticals, 1425 U.S. Route 206, Bedminster, NJ 07921, USATel +1 747 239 0007Fax +1 314 654 9440Email Nancy.Mahler@mnk.comPurpose: Repository corticotropin injection (RCI) is indicated for a number of autoimmune-mediated diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis (DM)/polymyositis (PM). To better understand the practice patterns and outcomes of RCI in patients with RA, SLE, or DM/PM, we conducted a retrospective medical record analysis.Patients and Methods: Participating providers selected deidentified medical records of patients meeting the inclusion criteria (age ≥ 18 years; physician-reported diagnosis of RA, SLE, or DM/PM; initiation of treatment with RCI between 1/1/2011 and 2/15/2016; ≥ 3 in-office visits with same site/provider). Collected data spanned 12 months before and after the first prescription date for RCI. Analyses included patient demographics and clinical history, RCI treatment patterns, and physician’s impression of change.Results: Data from 54 patients with RA, 30 patients with SLE, and 8 patients with DM/PM were analyzed. The most frequently reported reasons for initiating RCI were lack of efficacy with prior treatment, acute exacerbation of disease, and use as add-on to ongoing therapy. The most common initial RCI dosing, 80 U twice weekly, was used for 84% of patients with RA, 75% with SLE, and 86% with DM/PM. The mean duration of treatment was 4.8, 6.5, and 6.8 months for RA, SLE, and DM/PM, respectively. Among the 57 patients with data on physician’s impression of change with RCI, 78.1% of patients with RA, 94.7% with SLE, and 66.7% with DM/PM had a rating of “improved,” and the mean time to best impression of change was 3.4, 4.3, and 3.4 months for RA, SLE, and DM/PM, respectively.Conclusion: This study reports the real-world patient profile, use patterns, and outcomes of patients who used RCI for the treatment of RA, SLE, and DM/PM. These data can inform appropriate use and clinical expectations when using RCI.Keywords: adrenocorticotropic hormone, analogue, ACTH, immunomodulatory, real-world patients
format	article
author	Ho-Mahler N Turner B Eaddy M Hanke ML Nelson WW
author_facet	Ho-Mahler N Turner B Eaddy M Hanke ML Nelson WW
author_sort	Ho-Mahler N
title	Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
title_short	Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
title_full	Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
title_fullStr	Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
title_full_unstemmed	Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
title_sort	treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis/polymyositis
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/986e4a77b8e6411cb2e8470a0d405a3f
work_keys_str_mv	AT homahlern treatmentwithrepositorycorticotropininjectioninpatientswithrheumatoidarthritissystemiclupuserythematosusanddermatomyositispolymyositis AT turnerb treatmentwithrepositorycorticotropininjectioninpatientswithrheumatoidarthritissystemiclupuserythematosusanddermatomyositispolymyositis AT eaddym treatmentwithrepositorycorticotropininjectioninpatientswithrheumatoidarthritissystemiclupuserythematosusanddermatomyositispolymyositis AT hankeml treatmentwithrepositorycorticotropininjectioninpatientswithrheumatoidarthritissystemiclupuserythematosusanddermatomyositispolymyositis AT nelsonww treatmentwithrepositorycorticotropininjectioninpatientswithrheumatoidarthritissystemiclupuserythematosusanddermatomyositispolymyositis
_version_	1718397893176459264

Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis

Ejemplares similares